Biblio Discovery — Demo Discovery Service

143 hasil

Menampilkan 1–20 · 0,35 detik · RSS

Jurnal

Therapeutic Advances in Rare Disease

Scopus

ISSN 2633-0040 · SAGE Publishing · 143 artikel di indeks

  1. Artikel Jurnal

    Eneboparatide induces prolonged 24-hour PTH 1 receptor activation

    Xavier Gaume PhD; Guillaume Ravel PhD; Corentin Berardet PhD dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background Chronic hypoparathyroidism (HypoPT) leads to hypocalcemia due to insufficient parathyroid hormone (PTH), with conventional oral calcium and vitamin D therapy often failing to provide stable regulation. Eneboparatide is a peptide designed to activate the PTH 1 receptor (PTH1R) with…

  2. Artikel Jurnal

    Addressing unmet needs in rare diseases: A patient-centred vision through INFORM-RD

    Kenji Demesure; Lien Beckers; Wendy Vansteenkiste dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Rare diseases collectively affect approximately 6% of the global population, yet 95% of affected individuals lack access to effective treatments. Beyond this persistent therapeutic gap, patients and caregivers face a broad spectrum of unmet needs, spanning psychosocial challenges, access to…

  3. Artikel Jurnal

    Evaluation of muscle microvascular perfusion in primary mitochondrial disease by contrast-enhanced ultrasound: Feasibility study

    Laith R. Sultan MD, MBMI; Trudy A. Morgan RDMS; Daniel E. McGinn MS dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background Primary mitochondrial disease (PMD) are genetic disorders characterized by impaired oxidative metabolism and microvascular abnormalities that contribute to the myopathy. Objectives This study evaluates the feasibility and utility of contrast-enhanced ultrasound (CEUS) for quantifying…

  4. Artikel Jurnal

    Endothelial–mitochondrial coupling in mitochondrial disease: A systematic review and quantitative synthesis of vascular, biochemical, and oxidative bioenergetic dysfunction

    Jose A. Adams; Tiffany Ko; Laith R. Sultan dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Introduction Mitochondrial diseases are multisystem disorders in which defects in oxidative phosphorylation disrupt cellular bioenergetics and redox signaling across the vasculature and heart. Because mitochondrial function is closely linked to endothelial nitric oxide (NO) production, we…

  5. Artikel Jurnal

    2000–2025: Emerging therapies in primary mitochondrial disease: A structured review, horizon scan, and roadmap for the future

    Amel Karaa; Maria Isabel G. Lopez Sanchez; Clare Stuart dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Primary mitochondrial diseases (PMD) are ultra-rare, genetically diverse disorders that impair cellular energy metabolism and typically present with multisystemic symptoms. Over the past decades, the therapeutic landscape of PMD has evolved substantially. Early trials of non-specific antioxidant…

  6. Artikel Jurnal

    Interim analysis of an international multi-site prospective natural history study evaluating the clinical presentation and progression of Leigh syndrome spectrum disorders

    Laura E. MacMullen; Katelynn D. Stanley; John Christodoulou dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background Leigh Syndrome Spectrum (LSS) is the most common pediatric mitochondrial disease syndromic presentation. However, its natural history has not been well-characterized, particularly across diverse populations. Objectives Information obtained through robust, prospective natural history…

  7. Artikel Jurnal

    Progress and perspectives in primary mitochondrial myopathy: Highlights from the 2025 mitochondrial medicine masterclass with a focus on TK2 deficiency

    Austin Larson; Jared Goettemoeller; Ken Goettemoeller dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    The inaugural United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine 2025 Masterclass focused on primary mitochondrial diseases (PMDs) especially primary mitochondrial myopathies (PMMs) and thymidine kinase 2 deficiency (TK2d). The Masterclass featured leading US experts in the…

  8. Artikel Jurnal

    Cancer prevalence in primary mitochondrial disease patients and their families

    Shrey Dalwadi; Nicole M. Engelhardt; Colleen C. Muraresku dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background: While somatic mitochondrial dysfunction occurs in diverse cancers, the association between oncogenesis and germline mitochondrial gene pathogenic variants remains unclear. Further, few clinical observations have been reported of cancer occurring in primary mitochondrial disease (PMD)…

  9. Artikel Jurnal

    Treatment outcomes maintained in Hunter syndrome patients: a case series on switching from idursulfase to idursulfase beta in Belarus

    Anna Kulpanovich

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Hunter syndrome (Mucopolysaccharidosis type II, MPS II) is a rare X-linked lysosomal storage disorder caused by iduronate-2-sulfatase deficiency, leading to glycosaminoglycan accumulation. Enzyme replacement therapy (ERT) with idursulfase is a standard treatment, although supply shortages may…

  10. Artikel Jurnal

    First bone marrow transplantation for mucopolysaccharidosis type I in Vietnam: a case report

    Le Nguyen-Ngoc-Quynh; Ngoc Can-Thi-Bich; Duong Dang-Anh dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Mucopolysaccharidosis type I (MPS-I) is an inherited lysosomal storage disorder characterized by alpha-L-iduronidase deficiency, leading to progressive multi-organ damage and fatal complications. Early treatment is crucial to improve outcomes, particularly in patients with severe phenotypes. We…

  11. Artikel Jurnal

    Patients’ lived experience of thymidine kinase 2 deficiency: the online survey-based assessment of TK2d patient perspectives study

    Amel Karaa; Asha Hareendran; Katie Waller dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background: Thymidine kinase 2 deficiency (TK2d) is an ultra-rare autosomal recessive mitochondrial disease characterized by progressive myopathy. Objectives: To understand patient experiences and the impact of TK2d on patient quality of life (QoL), and to explore support needs. Design: A…

  12. Artikel Jurnal

    Patient and caregiver perspectives on neurodevelopmental and mental health care for RASopathies

    Evelyn M. Elizondo; Anne M. Floyd; Allison M. H. Foy dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background: Clinical studies have begun to evaluate therapeutic approaches to address the widespread neurodevelopmental and mental health challenges associated with a group of genetic syndromes known as “RASopathies.” However, the perspectives of patients and families regarding the relevance and…

  13. Artikel Jurnal

    A novel therapy for pyridoxine-dependent epilepsy due to biallelic pathogenic variants in : secondary mitochondrial energy deficiency and improvements of neurodevelopmental outcomes on triheptanoin treatment

    Anastasia Ambrose; Morganne McCabe; Shalini Bahl dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background: Pyridoxine-dependent epilepsy (PDE) due to biallelic pathogenic variants in ALDH7A1 (PDE-ALDH7A1) is an metabolic disease of lysine catabolism. Current standard treatment includes pyridoxine, arginine, and lysine- or protein-restricted diet. Pyridoxine treats seizures. Arginine and…

  14. Artikel Jurnal

    Challenges and opportunities for the use of telehealth in rare disease diagnosis, treatment, research, and education: key opinion leader interviews by the IRDiRC telehealth task force

    Melissa A. Parisi; Adam L. Hartman; Mary Catherine V. Letinturier dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    The International Rare Diseases Research Consortium (IRDiRC) Telehealth (TH) Task Force explored the use of TH for improving diagnosis, care, research, and education for rare diseases (RDs) worldwide. The Task Force members interviewed 23 key opinion leaders (KOLs), providing perspectives from…

  15. Artikel Jurnal

    The PBC Ireland patient registry: study protocol for a national platform on primary biliary cholangitis

    Gerry Nesbitt; Alexandra Curley

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background: Primary Biliary Cholangitis (PBC) is a chronic, progressive liver disease. This paper outlines how a PBC patient registry was developed to address the gaps in evidence, care and policy affecting PBC patients in Ireland. Objectives: The PBC patient registry is designed to collect…

  16. Artikel Jurnal

    Reliability assessment using the test–retest method and minimal important changes in the Adult Fabry Disease Quality of Life Scale

    Yuta Koto; Masami Tanaka; Mitsuyo Ishiura dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background: Fabry disease is rare and multisystemic, necessitating a disease-specific quality of life scale to assess changes in quality of life. We developed the Adult Fabry Disease Quality of Life scale to measure the quality of life of adult patients with Fabry disease. Objectives: To confirm…

  17. Artikel Jurnal

    Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease

    Robert J. Hopkin; Barry J. Byrne; Mazen M. Dimachkie dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Late-onset Pompe disease (LOPD) is a rare inherited disorder caused by deficiency of the lysosomal enzyme acid α-glucosidase (GAA), leading to an accumulation of lysosomal glycogen in tissues, profoundly affecting muscles. Patients with LOPD typically have some residual GAA activity but experience…

  18. Artikel Jurnal

    Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials

    Henning Andersen; Jordi Díaz-Manera; Ozlem Goker-Alpan dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background: Late-onset Pompe disease (LOPD) is caused by a deficiency of the acid α-glucosidase enzyme. In LOPD treatment, enzyme replacement therapy is delivered via intravenous infusion, typically in clinical settings. Cipaglucosidase alfa is delivered with the oral enzyme stabilizer miglustat…

  19. Artikel Jurnal

    Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy

    Arif Mitha; Victoria Hodgkinson; Susi Vander Wyk dkk.

    Therapeutic Advances in Rare Disease, Vol. 7 · 2026 · Inggris · DOAJ Scopus

    Background: Outcome-based agreements (OBAs) may facilitate earlier patient access to promising therapies, particularly when evidence is limited. The authors of this paper investigated how to operationalize an OBA using real-world data (RWD) from the Canadian Neuromuscular Disease Registry (CNDR)…